Skip to content
Accenture plc's (NYSE:ACN) price-to-earnings (or "P/E") ratio of 28.5x might make it look like a strong sell right now......
Top news and what to watch in the markets on Monday, July 20, 2020....
Intel's autonomous driving unit Mobileye scores another big win, this one with auto giant Ford....
VANCOUVER, BC and ERIE Pa., July 20, 2020 /CNW/ - ImagineAR Inc. (CSE: IP) (OTCQB: IPNFF) ("ImagineAR" or "Company") an Augmented Reality Company that enables sports teams, businesses, retailers and organizations to instantly create their own AR mobile campaigns, is pleased to announce the signing of an MOU with Loop Insights Inc. (TSXV: MTRX) ("Loop"), a provider of contactless solutions and Artificial Intelligence ("AI") to drive marketing and real-time consumer insights. The integration of each company's respective technologies into a singular platform will deliver personalized promotions and targeted engagement, leading to higher conversions and transaction revenue in the professional sports, entertainment and retail industries. On July 13, 2020 Loop announced the acceleration of conversations and projects with two of Canada's largest telecommunications companies, as well as, two of the largest network providers in the United States....
Ant Group, the fintech arm of Chinese e-commerce giant Alibaba, said on Monday that it had started the process of a concurrent initial public offering on Shanghai's Nasdaq-style Star Market and the Hong Kong Stock Exchange. The world's most valuable tech "unicorn" said in a release that the listings will help the company accelerate its goal of digitising the service industry in China, develop global markets with partners and expand investment in technology and innovation. Ant did not disclose the size, timetable or other details of the offering in the release....
AbbVie’s (ABBV) Allergan has told Molecular Partners that it will withdraw application filings with both the European Medicines Agency (EMA) and the Japanese Regulatory Agency (PMDA) for Abicipar pegol, a novel DARPin therapeutic for patients with neovascular (wet) age-related macular degeneration (nAMD).Age-related macular degeneration (AMD) occurs when a part of the retina called the macula is damaged, resulting in disturbance to the central visual field. Wet nAMD is less common but much more serious than dry AMD. Wet AMD is when new, abnormal blood vessels grow under the retina, causing scarring of the macula.In June 26, the U.S. Food and Drug Administration (FDA) rejected the Biologics License Application (BLA) for Abicipar pegol.According to the FDA’s Complete Response Letter, the rate of intraocular inflammation observed following administration of Abicipar pegol 2mg/0.05 mL resulted in an unfavorable benefit-risk ratio in the treatment of nAMD.“We continue to believe in the need for treatment options that provide patients with...
